ChemoCentryx, Inc. (CCXI)
Pre-Market:
| Previous Close | 25.34 |
| Open | 25.95 |
| Bid | 22.82 x 800 |
| Ask | 26.95 x 1300 |
| Day's Range | 24.81 - 26.97 |
| 52 Week Range | 9.53 - 70.29 |
| Volume | |
| Avg. Volume | 1,473,404 |
| Market Cap | 1.783B |
| Beta (5Y Monthly) | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. This approval follows the U.S. Food and Drug Administrati
- GlobeNewswire
ChemoCentryx to Present at Two Upcoming Investor Conferences
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan Healthcare ConferenceWednesday, January 12 at 4:30 p.m. Eastern Time H.C. Wainwright Virtual BioConnect ConferenceOn-demand presentation available beginning Monday, January 10 at 7:00 a.m. Eastern Time A live audio webcast of the J.P. Morgan presenta
- GlobeNewswire
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active g
